JP4968844B2 - 局所用ネパフェナク処方物 - Google Patents
局所用ネパフェナク処方物 Download PDFInfo
- Publication number
- JP4968844B2 JP4968844B2 JP2007544521A JP2007544521A JP4968844B2 JP 4968844 B2 JP4968844 B2 JP 4968844B2 JP 2007544521 A JP2007544521 A JP 2007544521A JP 2007544521 A JP2007544521 A JP 2007544521A JP 4968844 B2 JP4968844 B2 JP 4968844B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mannitol
- carbomer
- nepafenac
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 68
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 title claims description 19
- 229960001002 nepafenac Drugs 0.000 title claims description 19
- 238000009472 formulation Methods 0.000 title description 7
- 230000000699 topical effect Effects 0.000 title description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 16
- 229960001631 carbomer Drugs 0.000 claims description 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
- 229930195725 Mannitol Natural products 0.000 claims description 10
- 239000000594 mannitol Substances 0.000 claims description 10
- 235000010355 mannitol Nutrition 0.000 claims description 10
- 239000003755 preservative agent Substances 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000002738 chelating agent Substances 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 230000002335 preservative effect Effects 0.000 claims description 8
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 7
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical group [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 7
- 239000002736 nonionic surfactant Substances 0.000 claims description 7
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 6
- 239000003002 pH adjusting agent Substances 0.000 claims description 6
- 239000008181 tonicity modifier Substances 0.000 claims description 6
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical group O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims description 6
- 229960004224 tyloxapol Drugs 0.000 claims description 6
- 229920001664 tyloxapol Polymers 0.000 claims description 6
- RFIMISVNSAUMBU-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(prop-2-enoxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC=C RFIMISVNSAUMBU-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 claims description 4
- 229940124274 edetate disodium Drugs 0.000 claims description 4
- 229940086737 allyl sucrose Drugs 0.000 claims description 3
- -1 benzalkonium halides Chemical class 0.000 claims description 3
- 150000003841 chloride salts Chemical class 0.000 claims description 3
- 229910001510 metal chloride Inorganic materials 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000004155 Chlorine dioxide Substances 0.000 claims description 2
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 claims description 2
- 229960001716 benzalkonium Drugs 0.000 claims description 2
- 235000019398 chlorine dioxide Nutrition 0.000 claims description 2
- 239000008213 purified water Substances 0.000 claims description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- ALDSXDRDRWDASQ-UHFFFAOYSA-N 2-(3-benzoylphenyl)acetic acid Chemical class OC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 ALDSXDRDRWDASQ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010015943 Eye inflammation Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- SOYCMDCMZDHQFP-UHFFFAOYSA-N amfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=CC=C1 SOYCMDCMZDHQFP-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明はネパフェナク(nepafenac)の局所的に投与可能な眼用処方物に関する。本発明の処方物は懸濁組成物である。
本発明の組成物はネパフェナクの水性の懸濁組成物である。その組成物は0.09〜0.11%(w/v)のネパフェナクを含む。その組成物は本質的にネパフェナク、カルボマー、非イオン性界面活性剤、張度調整剤、pH調整剤、精製水、ならびに必要に応じて保存剤およびキレート剤からなる。
他に示されない限り、すべての成分の濃度は重量/体積%(% w/v)の単位で示される。
下の表1Aに示される処方物を調製し、そしてそれらのインビトロの角膜透過速度を比較した。角膜透過速度を、Keら,Inflammation,24(4):371−384(2000)に記述されている方法に従い、新たに単離されたウサギの角膜を用いて、灌流槽において評価した。その角膜透過の結果を表1Bに示す。
Claims (20)
- 局所的に投与可能な眼用組成物であって、該組成物は、
a)0.09〜0.11%(w/v)のネパフェナク;
b)0.4〜0.6%(w/v)のカルボマー;
c)非イオン性界面活性剤;
d)該組成物に250〜350mOsm/kgの重量オスモル濃度を持たせるのに十分な量の張度調整剤;
e)該組成物に7.0〜7.8のpHを持たせるのに十分な量のpH調整剤;および
f)水;
からなり、該組成物は保存剤およびキレート剤からなる群から選択される成分を必要に応じて含む、組成物。 - 前記組成物が0.1%(w/v)のネパフェナクを含む、請求項1に記載の組成物。
- 前記組成物が0.5%(w/v)のカルボマーを含む、請求項1に記載の組成物。
- 前記カルボマーがアリルスクロースまたはアリルペンタエリトリトールと架橋されたアクリル酸重合体である、請求項1に記載の組成物。
- 前記非イオン性界面活性剤がチロキサポールである、請求項1に記載の組成物。
- 前記組成物が0.01%(w/v)のチロキサポールを含む、請求項5に記載の組成物。
- 前記張度調整剤が金属塩化物塩およびマンニトールからなる群から選択される、請求項1に記載の組成物。
- 前記張度調整剤が塩化ナトリウムおよびマンニトールを含む、請求項7に記載の組成物。
- 前記組成物が0.3〜0.5%(w/v)の塩化ナトリウムおよび2〜3%(w/v)のマンニトールを含む、請求項8に記載の組成物。
- 前記組成物が0.4%(w/v)の塩化ナトリウムおよび2.4%(w/v)のマンニトールを含む、請求項9に記載の組成物。
- 前記pH調整剤が、塩酸および水酸化ナトリウムからなる群から選択される、請求項1に記載の組成物。
- 前記組成物が7.3〜7.7のpHを持つ、請求項1に記載の組成物。
- 前記組成物が保存剤およびキレート剤の両方を含む、請求項1に記載の組成物。
- 前記保存剤がハロゲン化ベンザルコニウム;ポリクオタニウム−1;および二酸化塩素からなる群から選択される、請求項1に記載の組成物。
- 前記保存剤が塩化ベンザルコニムである、請求項1に記載の組成物。
- 前記組成物が0.005%の塩化ベンザルコニウムを含む、請求項15に記載の組成物。
- 前記キレート剤がエデト酸二ナトリウム;エデト酸三ナトリウム;エデト酸四ナトリウム;およびジエチレンアミンペンタアセテートからなる群から選択される、請求項1に記載の組成物。
- 前記組成物が0.001〜0.1%(w/v)のエデト酸二ナトリウムを含む、請求項17に記載の組成物。
- 患者における眼の炎症障害を処置するための、請求項1に記載の組成物。
- 局所的に投与可能な眼用組成物であって、該組成物は、
a)0.1%(w/v)のネパフェナク;
b)0.5%(w/v)のカルボマー;
c)0.01%(w/v)のチロキサポール;
d)0.4%(w/v)の塩化ナトリウム;
e)2.4%(w/v)のマンニトール;
f)該組成物に7.3〜7.7のpHを持たせるのに十分な量のpH調整剤;
g)0.005%(w/v)の塩化ベンザルコニウム
h)0.01%のエデト酸二ナトリウム;および
i)精製水
からなる、組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63256204P | 2004-12-02 | 2004-12-02 | |
US60/632,562 | 2004-12-02 | ||
PCT/US2005/043545 WO2006060618A2 (en) | 2004-12-02 | 2005-12-02 | Topical nepafenac formulations |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011257966A Division JP2012041368A (ja) | 2004-12-02 | 2011-11-25 | 局所用ネパフェナク処方物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008521926A JP2008521926A (ja) | 2008-06-26 |
JP2008521926A5 JP2008521926A5 (ja) | 2008-10-30 |
JP4968844B2 true JP4968844B2 (ja) | 2012-07-04 |
Family
ID=35848959
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007544521A Active JP4968844B2 (ja) | 2004-12-02 | 2005-12-02 | 局所用ネパフェナク処方物 |
JP2011257966A Withdrawn JP2012041368A (ja) | 2004-12-02 | 2011-11-25 | 局所用ネパフェナク処方物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011257966A Withdrawn JP2012041368A (ja) | 2004-12-02 | 2011-11-25 | 局所用ネパフェナク処方物 |
Country Status (24)
Country | Link |
---|---|
US (3) | US7834059B2 (ja) |
EP (1) | EP1819362B1 (ja) |
JP (2) | JP4968844B2 (ja) |
KR (1) | KR101289661B1 (ja) |
CN (1) | CN101068573A (ja) |
AR (1) | AR052252A1 (ja) |
AT (1) | ATE476200T1 (ja) |
AU (1) | AU2005311738B2 (ja) |
BR (1) | BRPI0518904B1 (ja) |
CA (1) | CA2586807C (ja) |
CY (1) | CY1110780T1 (ja) |
DE (1) | DE602005022756D1 (ja) |
DK (1) | DK1819362T3 (ja) |
ES (1) | ES2348249T3 (ja) |
HK (1) | HK1104225A1 (ja) |
MX (1) | MX2007006558A (ja) |
PL (1) | PL1819362T3 (ja) |
PT (1) | PT1819362E (ja) |
RU (1) | RU2007124638A (ja) |
SI (1) | SI1819362T1 (ja) |
TW (1) | TWI358290B (ja) |
UY (1) | UY29238A1 (ja) |
WO (1) | WO2006060618A2 (ja) |
ZA (1) | ZA200704763B (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
SI1906916T1 (sl) * | 2005-05-10 | 2009-02-28 | Alcon Inc | Oftalmična suspenzija, ki obsega oftalmično zdravilo, poloksamin in glikolno sredstvo za naravnavo toničnosti, uporaba sestavka za pripravo zdravila za zdravljenje oftalmičnih motenj |
KR20080011310A (ko) * | 2005-05-10 | 2008-02-01 | 알콘, 인코퍼레이티드 | 폴록사머 또는 메록사폴 계면활성제 및 글리콜을유효성분으로 함유하는 현탁제, 안질환 치료용 의약의제조를 위한 그의 용도 |
TW200812575A (en) * | 2006-04-28 | 2008-03-16 | Alcon Inc | Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye |
US20080057022A1 (en) * | 2006-08-30 | 2008-03-06 | Erning Xia | Ophthalmic Pharmaceutical Compositions and Uses Thereof |
CA2687717A1 (en) * | 2007-05-24 | 2008-12-18 | Aciex Therapeutics, Inc. | Formulations and methods for treating dry eye |
TWI531362B (zh) * | 2008-07-21 | 2016-05-01 | 艾爾康股份有限公司 | 具有治療劑遞送能力之眼科裝置 |
TW201023912A (en) * | 2008-12-05 | 2010-07-01 | Alcon Res Ltd | Pharmaceutical suspension |
US8912236B2 (en) * | 2009-03-03 | 2014-12-16 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye |
BRPI1008920A2 (pt) * | 2009-03-03 | 2015-08-25 | Alcon Res Ltd | Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho |
PL2586426T3 (pl) | 2009-12-03 | 2016-01-29 | Alcon Res Ltd | Zawiesiny zawierające nanocząsteczkowe polimery karboksywinylowe |
US9544143B2 (en) | 2010-03-03 | 2017-01-10 | Duo Security, Inc. | System and method of notifying mobile devices to complete transactions |
US9532222B2 (en) | 2010-03-03 | 2016-12-27 | Duo Security, Inc. | System and method of notifying mobile devices to complete transactions after additional agent verification |
US9467463B2 (en) | 2011-09-02 | 2016-10-11 | Duo Security, Inc. | System and method for assessing vulnerability of a mobile device |
CA2859583C (en) * | 2011-12-16 | 2020-02-18 | Allergan, Inc. | Ophthalmic compositions comprising polyvinyl capralactam-polyvinyl acetate-polyethylene glycol graft copolymer |
US9630909B2 (en) | 2013-06-27 | 2017-04-25 | Mylan Laboratories Ltd | Process for the preparation of nepafenac |
CN104490861A (zh) * | 2014-11-21 | 2015-04-08 | 三明欣茂药业有限公司 | 一种缓释型奈帕芬胺眼用制剂 |
US10596107B2 (en) | 2015-01-26 | 2020-03-24 | Bausch & Lomb Incorporated | Ophthalmic suspension composition |
ES2758755T3 (es) | 2015-06-01 | 2020-05-06 | Duo Security Inc | Método para aplicar normas de salud de punto final |
CN107024550A (zh) * | 2016-12-21 | 2017-08-08 | 广州仁恒医药科技股份有限公司 | 奈帕芬胺眼用药物组合物的质控方法 |
CN106963730A (zh) * | 2016-12-22 | 2017-07-21 | 广州仁恒医药科技股份有限公司 | 高度稳定的奈帕芬胺眼用药物组合物 |
US10412113B2 (en) | 2017-12-08 | 2019-09-10 | Duo Security, Inc. | Systems and methods for intelligently configuring computer security |
US11658962B2 (en) | 2018-12-07 | 2023-05-23 | Cisco Technology, Inc. | Systems and methods of push-based verification of a transaction |
JP6994061B2 (ja) * | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤 |
CN114272207B (zh) * | 2022-01-21 | 2023-04-11 | 山东诺明康药物研究院有限公司 | 一种纳米晶混悬滴眼液及其制备方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1226344A (ja) * | 1967-07-31 | 1971-03-24 | ||
SE400966B (sv) * | 1975-08-13 | 1978-04-17 | Robins Co Inc A H | Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror |
US4313949A (en) * | 1979-09-26 | 1982-02-02 | A. H. Robins Company, Inc. | Method of producing an inhibitory effect on blood platelet aggregation |
US4254146A (en) * | 1979-10-18 | 1981-03-03 | A. H. Robins Company, Inc. | 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters |
IL61945A (en) | 1980-02-19 | 1984-09-30 | Robins Co Inc A H | 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them |
US4503073A (en) * | 1981-01-07 | 1985-03-05 | A. H. Robins Company, Incorporated | 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids |
IL64724A0 (en) | 1981-02-17 | 1982-03-31 | Robins Co Inc A H | 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them |
US4568695A (en) * | 1983-12-07 | 1986-02-04 | A. H. Robins Company, Incorporated | 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor |
US4851443A (en) * | 1985-03-14 | 1989-07-25 | Smith Kline Dauelsberg, Gmbh | Carboxylic acid amides, compositions and medical use thereof |
DE3668450D1 (de) * | 1985-03-14 | 1990-03-01 | Smithkline Dauelsberg | 5-aminosalicylsaeurederivate von nicht-steroidalen entzuendungshemmenden sauren. |
US4683242A (en) * | 1985-10-28 | 1987-07-28 | A. H. Robins Company, Incorporated | Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters |
DK406686D0 (da) * | 1986-08-26 | 1986-08-26 | Hans Bundgaard | Carboxylsyrederivater |
US4910225A (en) * | 1988-01-27 | 1990-03-20 | Senju Pharmaceutical Co., Ltd. | Locally administrable therapeutic composition for inflammatory disease |
US5521222A (en) * | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
US5461081A (en) * | 1989-09-28 | 1995-10-24 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
US5624893A (en) * | 1993-10-14 | 1997-04-29 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation |
US5475034A (en) * | 1994-06-06 | 1995-12-12 | Alcon Laboratories, Inc. | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
US6066671A (en) * | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
AR030345A1 (es) * | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes relacionados con angiogenesis |
AR030346A1 (es) * | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico |
AU2003231730A1 (en) * | 2002-05-03 | 2003-11-17 | Alcon, Inc. | Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac |
JP4500261B2 (ja) * | 2003-01-21 | 2010-07-14 | 千寿製薬株式会社 | 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性液剤 |
TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
-
2005
- 2005-11-23 TW TW094141182A patent/TWI358290B/zh active
- 2005-11-28 AR ARP050104964A patent/AR052252A1/es not_active Application Discontinuation
- 2005-11-29 UY UY29238A patent/UY29238A1/es not_active Application Discontinuation
- 2005-12-02 CN CNA200580041442XA patent/CN101068573A/zh active Pending
- 2005-12-02 SI SI200531107T patent/SI1819362T1/sl unknown
- 2005-12-02 DE DE602005022756T patent/DE602005022756D1/de active Active
- 2005-12-02 AU AU2005311738A patent/AU2005311738B2/en active Active
- 2005-12-02 BR BRPI0518904-7A patent/BRPI0518904B1/pt active IP Right Grant
- 2005-12-02 DK DK05825662.9T patent/DK1819362T3/da active
- 2005-12-02 EP EP05825662A patent/EP1819362B1/en active Active
- 2005-12-02 US US11/292,484 patent/US7834059B2/en active Active
- 2005-12-02 ES ES05825662T patent/ES2348249T3/es active Active
- 2005-12-02 CA CA2586807A patent/CA2586807C/en active Active
- 2005-12-02 RU RU2007124638/15A patent/RU2007124638A/ru unknown
- 2005-12-02 KR KR1020077012413A patent/KR101289661B1/ko active IP Right Review Request
- 2005-12-02 WO PCT/US2005/043545 patent/WO2006060618A2/en active Application Filing
- 2005-12-02 PL PL05825662T patent/PL1819362T3/pl unknown
- 2005-12-02 MX MX2007006558A patent/MX2007006558A/es active IP Right Grant
- 2005-12-02 JP JP2007544521A patent/JP4968844B2/ja active Active
- 2005-12-02 ZA ZA200704763A patent/ZA200704763B/xx unknown
- 2005-12-02 AT AT05825662T patent/ATE476200T1/de active
- 2005-12-02 PT PT05825662T patent/PT1819362E/pt unknown
-
2007
- 2007-09-25 HK HK07110438.2A patent/HK1104225A1/xx unknown
-
2010
- 2010-09-14 CY CY20101100830T patent/CY1110780T1/el unknown
- 2010-09-23 US US12/888,631 patent/US8071648B2/en active Active
-
2011
- 2011-10-05 US US13/253,648 patent/US8324281B2/en active Active
- 2011-11-25 JP JP2011257966A patent/JP2012041368A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4968844B2 (ja) | 局所用ネパフェナク処方物 | |
JP4968954B2 (ja) | 活性成分、ポロキサマー界面活性剤もしくはメロキサポール界面活性剤およびグリコールを含有する懸濁処方物、ならびに眼の障害を処置するための医薬の製造のためのその使用 | |
JP4968955B2 (ja) | 眼用薬物、ポロキサミンおよびグリコール張度調整剤を含有する眼用懸濁液、ならびに眼の障害を処置するための医薬の製造のためのこの組成物の使用 | |
JP2018030871A (ja) | 非刺激性の眼科用ポビドンヨード組成物 | |
RU2009149687A (ru) | Фармацевтические композиции и способы лечения сухих кератитов | |
JP2008521926A5 (ja) | ||
JP2011132259A (ja) | コンタクトレンズでの使用に適する眼の抗アレルギー組成物 | |
US5895645A (en) | Opthalmic solution for artificial tears | |
JP2006528990A5 (ja) | ||
JP2001097865A (ja) | 眼科用組成物 | |
JP2002316926A (ja) | コンタクトレンズ用眼科用組成物及び眼刺激性の緩和方法 | |
JP2009161454A (ja) | 眼科用組成物 | |
JP4849288B2 (ja) | 点眼剤及び涙液膜の安定化剤 | |
JP2003073303A (ja) | 眼局所用液剤の清涼化作用の持続方法 | |
JP2012006962A (ja) | 眼科用組成物 | |
JP2009084235A (ja) | 眼科用抗充血剤及び抗充血用眼科組成物 | |
JPH1192368A (ja) | ベンゾピラン誘導体を主成分とする水性液剤 | |
JP6401699B2 (ja) | 両性イオン性ソフトコンタクトレンズ用眼科用組成物 | |
JP2001097861A (ja) | 眼科用組成物 | |
JP2005239681A (ja) | 眼科用剤 | |
JP2006219487A (ja) | アレルギー性結膜疾患治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080905 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080905 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111003 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111125 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120329 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120330 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150413 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4968844 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |